Barrett'S Esophagus Clinical Trials 2022

Browse 18 Barretts Esophagus Medical Studies Across 45 Cities

97 Barretts Esophagus Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates
3
Effectiveness
3
Safety

Group 4for Barrett Esophagus

Washington, United States
18+
All Sexes
In this prospective single center study, up to 25 patients with Barrett's esophagus with LGD or no dysplasia (Group 1), 25 patients with HGD/IMCA (Group 2), 25 patients with esophageal carcinoma confined to the esophageal wall (Group 3) and 25 patients with severe esophageal squamous dysplasia (Group 4) will be treated with endoscopic cryotherapy. This study is single arm and no blinding will be utilized. Interim analysis of the data will be reviewed with a DCI statistician after 14 patients in each group have been treated with cryotherapy and if safety and efficacy is documented to that point in time, we will request the ability to extend the enrollment to a maximum allowable amount of 25 patients per group. The proposed study duration is seven years, allowing two years for patient enrollment and 5 years for post treatment follow-up. Study duration per patient will total approximately six years. Patients with Barrett's esophagus with no dysplasia or low grade dysplasia (group 1) will be treated with cryotherapy at six week intervals until Barrett's mucosa is ablated or six treatments are administered. Patients with Barrett's HGD and IMCA or severe esophageal squamous dysplasia (groups 2 and 4) will be treated with cryotherapy at six-week intervals until Barrett's mucosa is ablated or six treatments are administered. More advanced mass lesions are typically more difficult to eradicate with ablative therapies and may progress faster than patients with IMCA, therefore, patients with more advanced cancer (group 3) will be treated every 2 weeks until the lesion is eradicated up to eight treatments. After cryotherapy treatment is complete (i.e. the esophagus has re-epithelialized with normal squamous epithelium for Groups 1, 2, 4 and the tumor is locally controlled/absent in Group 3), patients will be assessed by endoscopy and biopsy every three months for one year, every six months for two years, then annually for two years (flow sheet - appendix 1; study schedule - appendix 2).
Phase 4
Waitlist Available
18 Barretts Esophagus Clinical Trials Near Me
San Francisco, CA
Philadelphia, PA
Philadelphia, PA
Saint Louis, MO
More Trial Locations
An interactive map to display trial locations for QURE Healthcare, Thomas Jefferson University Hospital, Fox Chase Cancer Center, Washington University in St. Louis, Barnes Jewish Hospital, and 39 more locations.
Most Popular References for Barretts Esophagus Clinical Trials
Frequency
Citation
Top Hospitals for Barretts Esophagus Clinical Trials
Location
Active Barretts Esophagus Clinical Trials
All Time Trials for Barretts Esophagus
First Recorded Barretts Esophagus Trial
Trials
Lucid Investigative Site, Knoxville, Tennessee
2
2
2020
Lucid Investigative Site, Shreveport, Louisiana
2
2
2020
Lucid Investigative Site, Rochester, New York
2
2
2020
Lucid Investigative Site, Salt Lake City, Utah
2
2
2020
Top Treatments for Barretts Esophagus Clinical Trials
Treatment Name
Active Barretts Esophagus Clinical Trials
All Time Trials for Barretts Esophagus
First Recorded Barretts Esophagus Trial
Trials
Post-EET Surveillance Group: WATS-3D samples followed by Forceps biopsies
1
1
2020
Tethered Capsule Endomicroscopy
1
1
2019
Top Cities for Barretts Esophagus Clinical Trials
City
Active Barretts Esophagus Clinical Trials
Top Active Site for Barretts Esophagus Clinical Trials
Trial List
Pediatric Barretts Esophagus Clinical Trials
Recently Completed Studies with FDA Approved Treatments for Barretts Esophagus
Treatment
Year
Mechanism of Action
Sponsor
Active Barretts Esophagus Clinical Trials
Alginates
2017
Potassium bicarbonate + Alginic acid
Medical University of South Carolina
0

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: August 7th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.